 | Up a level |
Journal Article
Joerger, M., Soo, R., Cho, B. C., Navarro Mendivil, A., Sayehli, C., Richly, H., Tai, D., Kim, D. -W., Wolf, J., Cassier, P., Ellinghaus, P., Hildebrandt, S., Behre, S., Helmbrecht, C., Kerpen, S., Zielinski, D., Ince, S., Rajagopalan, P., Ocker, M. and Schuler, M. (2016). Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Schuler, M., Nogova, L., Heidenreich, A., Tai, D., Cassier, P., Richly, H., Cho, B. C., Sayehli, C. M., Navarro, A., Bender, S., Ocker, M., Nogai, H., Wagner, A., Ince, S., Ellinghaus, P. and Joerger, M. (2017). Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041